Status: Recruiting
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Participants needed: 25
Trial details
Phase: Phase 2Age: 21+Biological sex: FemaleType: InterventionalSponsor: Jonsson Comprehensive Cancer CenterUpdated: Mar 10, 2026Locations: 1
Eligibility criteria
Female participants who are at least 21 years of age on the day of signing infor... [+8]
A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocat... [+24]